CHICAGO — Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks, according to the results of the ALPACAR trial.The phase 2 ALPACAR trial, results of which were presented at the American Heart Association Scientific Sessions and simultaneously published in JAMA, included 178 patients (mean age, 63.7 years;
In 1929, Drury and Szent-Gyorgi 1 published their findings on the cardiovascular effects of the endogenous purine adenosine. This publication marked the beginning of over…
It’s not the “blues” you’re having, but the “mean reds.” It can be hard to spot the signs of an impending burnout, and Dr. Emma…
Howie and Harlan are joined by Vin Gupta, a physician, a medical analyst for NBC News, and the chief medical officer of Amazon Pharmacy. Harlan…
The Azerbaijan Cardiology Festival, organized by the Azerbaijan Society of Cardiology in partnership with the Azerbaijan Society of Nephrology, the Azerbaijan Society of Endocrinologists, and…
Learn how a heart attack differs from cardiac arrest and heart failure, and why it’s important to know the difference.
Specialized single-use, single-modality models often have limited or no generalization to new diseases, modalities, and clinical tasks. Foundation models are built for multipurpose use, enabling…
Chiara De Biase, Sam Dawkins and Francesco Maisano highlight sessions analyzing the latest trial evidence, including the two-year data from the MiCLASP and CLASP IID…
كرر أحمد عمر مدرب فريق الاتحاد السكندري لكرة السلة، تفوقه على منافسه الإسباني أوجستي بوش المدير الفني للنادي الأهلي، بعدما أعاد لقب بطولة كأس السوبر…
